These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 7701146)

  • 41. Sample-size calculation and reestimation for a semiparametric analysis of recurrent event data taking robust standard errors into account.
    Ingel K; Jahn-Eimermacher A
    Biom J; 2014 Jul; 56(4):631-48. PubMed ID: 24817598
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A brief overview of pilot studies and their sample size justification.
    Kunselman AR
    Fertil Steril; 2024 Jun; 121(6):899-901. PubMed ID: 38331310
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bayesian sample size determination for a clinical trial with correlated continuous and binary outcomes.
    Stamey JD; Natanegara F; Seaman JW
    J Biopharm Stat; 2013; 23(4):790-803. PubMed ID: 23786161
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blinded sample size reestimation with negative binomial counts in superiority and non-inferiority trials.
    Friede T; Schmidli H
    Methods Inf Med; 2010; 49(6):618-24. PubMed ID: 20686735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inferior thalamic peduncle deep brain stimulation for treatment-refractory obsessive-compulsive disorder: A phase 1 pilot trial.
    Lee DJ; Dallapiazza RF; De Vloo P; Elias GJB; Fomenko A; Boutet A; Giacobbe P; Lozano AM
    Brain Stimul; 2019; 12(2):344-352. PubMed ID: 30514614
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sample size reassessment in non-inferiority trials. Internal pilot study designs with ANCOVA.
    Friede T; Kieser M
    Methods Inf Med; 2011; 50(3):237-43. PubMed ID: 20213039
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distribution of the two-sample t-test statistic following blinded sample size re-estimation.
    Lu K
    Pharm Stat; 2016 May; 15(3):208-15. PubMed ID: 26865383
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Power and sample size calculation incorporating misspecifications of the variance function in comparative clinical trials with over-dispersed count data.
    Igeta M; Takahashi K; Matsui S
    Biometrics; 2018 Dec; 74(4):1459-1467. PubMed ID: 29579337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis.
    Friede T; Kieser M
    Pharm Stat; 2011; 10(1):8-13. PubMed ID: 19943322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A practical approach for comparing means of two groups without equal variance assumption.
    Wang H; Chow SC
    Stat Med; 2002 Oct; 21(20):3137-51. PubMed ID: 12369087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of repetitive transcranial magnetic stimulation over supplementary motor area in patients with schizophrenia with obsessive-compulsive-symptoms: A pilot study.
    Mendes-Filho VA; de Jesus DR; Belmonte-de-Abreu P; Cachoeira CT; Rodrigues Lobato MI
    Psychiatry Res; 2016 Aug; 242():34-38. PubMed ID: 27254652
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Blinded sample size recalculation in clinical trials with binary composite endpoints.
    Sander A; Rauch G; Kieser M
    J Biopharm Stat; 2017; 27(4):705-715. PubMed ID: 27295402
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Number needed to treat].
    Duca P
    Epidemiol Prev; 2002; 26(2):87-9. PubMed ID: 12125391
    [No Abstract]   [Full Text] [Related]  

  • 55. Average bioequivalence evaluation: general methods for pilot trials.
    Pan G; Wang Y
    J Biopharm Stat; 2006; 16(2):207-25. PubMed ID: 16584068
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blinded sample size reestimation with count data: methods and applications in multiple sclerosis.
    Friede T; Schmidli H
    Stat Med; 2010 May; 29(10):1145-56. PubMed ID: 20146203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Test for the consistency of noninferiority from multiple clinical trials.
    Yan X; Wang MC; Su X
    J Biopharm Stat; 2007; 17(2):265-78. PubMed ID: 17365223
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A practical approach for comparing means of two groups without equal variance assumption: H. Wang and S. Chow, Statistics in Medicine 2002; 21:3137-3151.
    Singer J
    Stat Med; 2005 Mar; 24(5):817-8. PubMed ID: 15696497
    [No Abstract]   [Full Text] [Related]  

  • 59. Sample size calculation for clinical trials in which entry criteria and outcomes are counts of events. ACIP Investigators. Asymptomatic Cardiac Ischemia Pilot.
    McMahon RP; Proschan M; Geller NL; Stone PH; Sopko G
    Stat Med; 1994 Apr; 13(8):859-70. PubMed ID: 8047740
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of trial design on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors.
    Larsen MS; Juul RV; Kreilgaard M; Kristensen AT; Simonsson USH
    Eur J Pharm Sci; 2018 Oct; 123():531-538. PubMed ID: 30077714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.